1. Home
  2. GROY vs SLN Comparison

GROY vs SLN Comparison

Compare GROY & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GROY
  • SLN
  • Stock Information
  • Founded
  • GROY 2020
  • SLN 1994
  • Country
  • GROY Canada
  • SLN United Kingdom
  • Employees
  • GROY 16
  • SLN N/A
  • Industry
  • GROY
  • SLN Biotechnology: Pharmaceutical Preparations
  • Sector
  • GROY
  • SLN Health Care
  • Exchange
  • GROY Nasdaq
  • SLN Nasdaq
  • Market Cap
  • GROY 618.0M
  • SLN 299.4M
  • IPO Year
  • GROY 2021
  • SLN N/A
  • Fundamental
  • Price
  • GROY $3.62
  • SLN $4.81
  • Analyst Decision
  • GROY Strong Buy
  • SLN Buy
  • Analyst Count
  • GROY 4
  • SLN 5
  • Target Price
  • GROY $4.58
  • SLN $32.60
  • AVG Volume (30 Days)
  • GROY 2.5M
  • SLN 61.8K
  • Earning Date
  • GROY 08-06-2025
  • SLN 08-07-2025
  • Dividend Yield
  • GROY N/A
  • SLN N/A
  • EPS Growth
  • GROY N/A
  • SLN N/A
  • EPS
  • GROY N/A
  • SLN N/A
  • Revenue
  • GROY $12,376,000.00
  • SLN $27,169,000.00
  • Revenue This Year
  • GROY $82.74
  • SLN N/A
  • Revenue Next Year
  • GROY $51.73
  • SLN N/A
  • P/E Ratio
  • GROY N/A
  • SLN N/A
  • Revenue Growth
  • GROY 90.37
  • SLN 22.28
  • 52 Week Low
  • GROY $1.16
  • SLN $1.97
  • 52 Week High
  • GROY $3.65
  • SLN $20.48
  • Technical
  • Relative Strength Index (RSI)
  • GROY 65.91
  • SLN 34.88
  • Support Level
  • GROY $2.89
  • SLN $4.91
  • Resistance Level
  • GROY $3.37
  • SLN $5.34
  • Average True Range (ATR)
  • GROY 0.15
  • SLN 0.48
  • MACD
  • GROY 0.01
  • SLN -0.05
  • Stochastic Oscillator
  • GROY 85.59
  • SLN 0.71

About GROY Gold Royalty Corp.

Gold Royalty Corp is a precious metals-focused royalty and mineral streaming company. The company offers creative financing solutions to the metals and mining industry. The company's mission is to acquire royalties, streams and similar interests at varying stages of the mine life cycle to build a balanced portfolio offering near, medium and longer-term attractive returns for investors. It has its business as a single operating segment, being the investment in royalty and mineral stream interests. The company derives maximum revenue from Canada.

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Share on Social Networks: